J. Klempnauer et al., RESECTIONAL SURGERY OF HILAR CHOLANGIOCARCINOMA - A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS, Journal of clinical oncology, 15(3), 1997, pp. 947-954
Purpose: To define the prognostic factors after surgical resection of
bile duct carcinomas at the hepatic bifurcation. Patients and Methods:
The retrospective single-center experience details 151 patients after
surgical resection of central bile duct carcinoma performed between 1
971 and 1995. Tumor removal was accomplished by resection of the bile
duct bifurcation either alone (group I, n = 33), in combination with h
epatic resection (group II, n = 77), or combined with hepatic and vasc
ular resection (group III, n = 41). Survival analysis was performed by
the Kaplan-Meier method and the relationship between each of the clin
icopathologic variables and survival was assessed by the log-rank test
. Multivariate results were confirmed using Cox regression. Results: T
he overall hospital mortality rate was 9.9% and depended on the extent
of resection (group I, 6.1%; group II, 7.8%; group III, 17.1%). After
exclusion of hospital deaths, the overall patient survival rate was 2
8.4% at 5 and 15.5% at 10 years, with a median survival duration of 2.
05 +/- 0.23 years. Univariate survival analysis identified tumor size,
lymph node metastases, residual tumor stage, and tumor grading as fac
tors with a statistically significant prognostic impact. Survival prog
nosis was not influenced by the site of the tumor according to the cla
ssification of Bismuth and Corlette, extent of resection, Internationa
l Union Against Cancer (UICC) stage, perineural and vascular invasion,
age, or sex. In a multivariate Cox analysis, only lymph node metastas
es and residual tumor stage proved to be of independent prognostic sig
nificance. Conclusion: Resection of central bile duct carcinoma is fea
sible in many patients and a favorable outcome after resection is main
ly determined by curative resection and the absence of lymph node meta
stases. (C) 1997 by American Society of Clinical Oncology.